Scutellarin inhibits hypoxia-induced epithelial-mesenchymal transition in bladder cancer cells

J Cell Physiol. 2019 Dec;234(12):23169-23175. doi: 10.1002/jcp.28883. Epub 2019 May 24.

Abstract

Scutellarin, an active component of flavonoid, displays a variety of physiological actions and has been applied for the treatment of diverse diseases including hypertension and cerebral infarction as well as cerebral thrombosis. In recent time, Scutellarin has been demonstrated to possess the anticancer activity. But the biological significance of Scutellarin in bladder cancer (BC) remains to be elucidated. In the current study, we explored the specific effect of Scutellarin on BC progression. We found that Scutellarin inhibited hypoxia-induced BC cell migration and invasion in vitro as well as suppressed hypoxia-induced BC metastasis in vivo. Moreover, Scutellarin significantly reversed hypoxia-promoted epithelial-mesenchymal transition (EMT) in BC cells and the PI3K/Akt and MAPK pathways were implicated in the suppressive effect. Taken together, we suggested the potential value of Scutellarin as a novel anticancer agent for BC treatment.

Keywords: Scutellarin; bladder cancer (BC); epithelial-mesenchymal transition (EMT); hypoxia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology*
  • Apigenin / pharmacology*
  • Cell Hypoxia / drug effects
  • Cell Line, Tumor
  • Cell Movement / drug effects
  • Epithelial-Mesenchymal Transition / drug effects*
  • Glucuronates / pharmacology*
  • Humans
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Urinary Bladder Neoplasms / pathology*
  • Xenograft Model Antitumor Assays

Substances

  • Antineoplastic Agents
  • Glucuronates
  • scutellarin
  • Apigenin